Z. Li

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing

A. Shamas-Din, L. Kay, S. Trudel, 2015, Cell Death and Disease.

A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer

X. Zhang, L. Zhang, X. Yang, 2022, ESMO open.